Contract Pharma Highlights Matt Niloff on CGT Manufacturing
We’re excited to share that Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, is featured in an article on current trends and challenges with CGT outsourcing in the June 2025 issue of Contract Pharma. Matt offers expert insights into the current state and future direction of gene therapy manufacturing, emphasizing the importance of scalability, speed, and operational excellence as more therapies move toward commercialization.
As a trusted CDMO partner in the gene therapy space, Andelyn Biosciences has earned a reputation for bringing both scientific rigor and strategic foresight to its partnerships. Matt’s commentary highlights how Andelyn is addressing growing market demand by investing in flexible infrastructure, expanding capabilities, and supporting clients from clinical development through commercial launch.